NeoImmuneTech is a pioneering clinical-stage biotech company based in Rockville, MD, dedicated to discovering and developing innovative immuno-therapeutics. With a strong focus on T cell research, NeoImmuneTech aims to expand the therapeutic possibilities in Immuno-Oncology and Infectious Diseases, aiming to reduce the fatality and morbidity associated with life-threatening illnesses. Led by their scientific founder, NeoImmuneTech has developed NT-I7 (efineptakin alfa), a long-acting human IL-7, which has shown promising potential in addressing key resistance mechanisms in Immuno-Oncology and combating deadly infectious diseases.

As a patient-centric company, NeoImmuneTech firmly believes in their ability to transform patient care through unique assets like NT-I7. With a commitment to scientific advancements, they continue to explore the full potential of their discoveries in the treatment of various diseases. Founded in 2014, NeoImmuneTech is driven by their passion for scientific innovation and their goal of making a significant impact on patient outcomes